Search

everythinglearnresearchcommunity

for

Search:↓

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

Blocking LFA-1 prevents hair loss in mice.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

CS12192 effectively treats alopecia areata with better safety than current options.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

Activating liver X receptors can reduce fibrosis by stopping certain immune cells from releasing harmful proteins.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.

Suppressing eIF4E can prevent hair loss from chemotherapy.

Lithocholic acid helps hair growth and regeneration in alopecia by activating vitamin D receptors.

Thymosin beta 4 protects cells from damage by blocking a harmful microRNA and boosting a protective gene.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

Enhancing Tregs can protect against alopecia areata.

LGD1069 effectively prevents breast tumors in mice without toxicity.

Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.

The compound 4c effectively inhibits the enzyme linked to hair loss.

High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Stopping TNFα inhibitors can help children regrow hair lost due to the medication.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Baricitinib 4 mg is effective and safe for treating severe alopecia areata.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.